Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.55 |
| ▸ | NOS2 | P35228 | 7/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | USP7 | Q93009 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169637 | 0.92 | NOS2 (0.54) | MBOAT4NOS2NFE2L2USP7KEAP1 | |
| SCHEMBL10169644 | 0.91 | MBOAT4 (0.52) | MBOAT4NOS2NFE2L2USP7KEAP1 | |
| SCHEMBL10169638 | 0.89 | CYP3A4 (0.56) | MBOAT4NOS2NFE2L2USP7KEAP1 | |
| SCHEMBL10169643 | 0.88 | NOS2 (0.53) | MBOAT4NOS2NFE2L2USP7KEAP1 | |
| SCHEMBL12958345 | 0.88 | MBOAT4 (0.45) | MBOAT4NOS2NFE2L2USP7KEAP1 | |
| SCHEMBL10169641 | 0.88 | NOS2 (0.53) | MBOAT4NOS2NFE2L2USP7KEAP1 | |
| SCHEMBL10169650 | 0.88 | NFE2L2 (0.56) | MBOAT4NOS2NFE2L2USP7KEAP1 | |
| SCHEMBL10169642 | 0.87 | NOS2 (0.50) | MBOAT4NOS2NFE2L2USP7KEAP1 | |
| SCHEMBL10169648 | 0.87 | MBOAT4 (0.58) | MBOAT4NOS2NFE2L2USP7KEAP1 | |
| SCHEMBL10169647 | 0.87 | NOS2 (0.52) | MBOAT4NOS2NFE2L2USP7KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701709-B2 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | REATA PHARMACEUTICALS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9670147-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150376121-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150259377-A1 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9102681-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-8993640-B2 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | REATA PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140323579-A1 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. | 2014-10-30 | — | — | US | disclosed |
| US-8440854-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8124799-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100048892-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376121-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | MBOAT4 415/4885NOS2 41/4885NFE2L2 9/4885 |
| US-20140323579-A1 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | CYP2A13, CYP4B1, CYP4A22 | MBOAT4 3396/4885NOS2 1348/4885NFE2L2 437/4885 |
| US-20100048892-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | MBOAT4 415/4885NOS2 41/4885NFE2L2 9/4885 |
| US-20150259377-A1 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | CYP2A13, CYP4B1, CYP4A22 | MBOAT4 3396/4885NOS2 1348/4885NFE2L2 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.